SPATA31E1

Chr 9

SPATA31 subfamily E member 1

Also known as: C9orf79, FAM75E1

The protein is predicted to be involved in cell differentiation and spermatogenesis and localizes to cellular membranes. Based on the low constraint scores (pLI 0.03, LOEUF 1.35) and predicted gain-of-function mechanism, mutations would likely cause disease through a dominant inheritance pattern, though specific neurological phenotypes have not been established. The gene's tolerance to loss-of-function variants suggests haploinsufficiency is unlikely to be pathogenic.

ResearchSummary from RefSeq, UniProt, Mechanism
MultiplemechanismLOEUF 1.35
Clinical SummarySPATA31E1
Population Constraint (gnomAD)
Low constraint (pLI 0.03) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
26 unique Pathogenic / Likely Pathogenic· 259 VUS of 300 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.35LOEUF
pLI 0.027
Z-score 1.04
OE 0.53 (0.241.35)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
-2.13Z-score
OE missense 1.21 (1.151.28)
958 obs / 789.5 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE0.53 (0.241.35)
00.351.4
Missense OE1.21 (1.151.28)
00.61.4
Synonymous OE1.08
01.21.6
LoF obs/exp: 3 / 5.7Missense obs/exp: 958 / 789.5Syn Z: -1.17
DN
0.75top 25%
GOF
0.80top 10%
LOF
0.2873th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

300 submitted variants in ClinVar

Classification Summary

Pathogenic21
Likely Pathogenic5
VUS259
Likely Benign14
Benign1
21
Pathogenic
5
Likely Pathogenic
259
VUS
14
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
21
0
21
Likely Pathogenic
0
0
5
0
5
VUS
0
252
7
0
259
Likely Benign
0
11
1
2
14
Benign
0
0
1
0
1
Total0263352300

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SPATA31E1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC

No open access results found